Isonicotinic acid hydrazide , 98% , 54-85-3

Synonym(s):
Isoniazid;INH;Isonicotinic acid hydrazide;Isonicotinic hydrazide;Isoniazide, 4-Pyridinecarbohydrazide, Isonicotinic acid hydrazide

CAS NO.：54-85-3

Empirical Formula: C6H7N3O

Molecular Weight: 137.14

MDL number: MFCD00006426

EINECS: 200-214-6

PRODUCT Properties

• Melting point: 171-173 °C (lit.)
• Boiling point: 251.97°C (rough estimate)
• Density: 1.2620 (rough estimate)
• refractive index: 1.6910 (estimate)
• Flash point: >250°C
• storage temp.: 2-8°C
• solubility: 125g/l
• pka: pKa 2.00/3.60/10.8(H2O) (Uncertain)
• form: Crystals or Crystalline Powder
• color: White or colorless
• PH: 6-8 (50g/l, H2O, 20℃)
• Odor: Odorless
• PH Range: 5.5 - 6.5 at 10 g/l at 25 °C
• Water Solubility: 14 g/100 mL (25 ºC)
• Sensitive: Air Sensitive
• Merck: 14,5186
• BRN: 119374
• BCS Class: 1,3
• Stability: Stability Stable, but may be air or light sensitive. Combustible. Incompatible with strong oxidizing agents, chloral, aldehydes, iodine, ferric salts, hypochlorites.
• InChIKey: QRXWMOHMRWLFEY-UHFFFAOYSA-N
• CAS DataBase Reference: 54-85-3(CAS DataBase Reference)
• IARC: 3 (Vol. 4, Sup 7) 1987
• NIST Chemistry Reference: Isoniazid(54-85-3)
• EPA Substance Registry System: Isoniazid (54-85-3)

Description and Uses

Isoniazid, the hydrazide of isonicotinic acid was introduced into medical practice for treating tuberculosis in 1953. Isoniazid exhibits bactericidal action on Mycobacterium tuberculosis. It inhibits the synthesis of mycolic acid, an important component of the cell membrane of mycobacteria. Mycolic acid is specific only to mycobacteria, and it is the cause of the selective toxicity of the drug with respect to these microorganisms.
Mutants that are resistant to isoniazid are rarely seen in nature, and in a spontaneously growing population of tuberculous bacillus there is approximately one mutant in every 105 –106 organisms. Large populations of microorganisms of the order 109 –1010 bacilli in the pulmonary cavities contain a significant number of resistant mutants. If only isoniazid is taken during treatment, an increased number of mutants will be observed and they will eventually become the dominant phenotype. The transformation from sensitive to nonsensitive microorganisms during treatment is called secondary or acquired resistance, which can originate over the course of a few weeks. Isoniazid is the most important drug for treating pulmonary and nonpulmonary forms of tuberculosis. It is active against both intracellular and extracellular organisms. In order to prevent secondary resistance, isoniazid should be used with other effective drugs (usually rifampin). Synonyms of this drug are tubazid, andrazide, niazid, piridizin, and many others.

Isoniazid is an antimicrobial used for the prevention of tuberculosis infection or used concurrently with another agent for the treatment of tuberculosis infection. Rifampin, pyrazinamide, or both of these agents are commonly used with isoniazid. Isoniazid is the only Food and Drug Administration approved drug to treat latent tuberculosis in order to prevent it from becoming active.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315
• Precautionary statements: P264-P270-P280-P301+P312-P302+P352-P332+P313
• Hazard Codes: Xn
• Risk Statements: 22-38-40-36/37/38
• Safety Statements: 37-36/37/39-26
• RIDADR: 2811
• WGK Germany: 3
• RTECS: NS1751850
• TSCA: Yes
• PackingGroup: III
• HS Code: 29333999
• Hazardous Substances Data: 54-85-3(Hazardous Substances Data)
• Toxicity: LD50 in mice (mg/kg): 151 i.p., 149 i.v. (Jenney, Pfeiffer)